With the release of outcomes from multiple phase 2 and phase 3 clinical trials, the multidisciplinary management protocols for early-stage resectable non-small cell lung cancer (rNSCLC) are experiencing expedited evolution. These studies have elucidated the pronounced efficacy of neoadjuvant and adjuvant therapies in enhancing the prognosis of rNSCLC patients, concurrently highlighting the imperative need for the revision and enhancement of congruent therapeutic regimens and clinical pathways. In light of this, the International Association for the Study of Lung Cancer (IASLC) has constituted a heterogeneous, multidisciplinary international consortium of experts to appraise ongoing clinical trials pertinent to rNSCLC, offering diagnostic, staging, and therapeutic recommendations for patients with stage Ⅱ and Ⅲ rNSCLC in accordance with the American Joint Committee on Cancer-Union for International Cancer Control, 8th Edition (AJCC-UICC 8th Edition). The document "Neoadjuvant and adjuvant therapy for early-stage resectable non-small cell lung cancer: Consensus recommendations from the International Association for the Study of Lung Cancer" enumerates a total of 20 recommendations, with 19 garnering consensus approval from over 85% of the experts. It is stipulated that patients with early-stage rNSCLC should undergo multidisciplinary team evaluations and complete requisite radiological assessments prior to definitive diagnosis. For patients with stage ⅢA or ⅢB, neoadjuvant chemotherapy and immunotherapy are advocated, whereas such therapies are not recommended for patients harboring epidermal growth factor receptor (EGFR) or anaplasticlymphoma kinase (ALK) mutations sensitive to tyrosine kinase inhibitors (TKIs). Postoperatively, adjuvant immunotherapy is considered contingent upon programmed cell death ligand 1 (PD-L1) expression levels, and additional oncogenic driver genes are scrutinized. For patients with specific genetic mutations, adjuvant therapy with osimertinib or alectinib is endorsed. These recommendations are designed to afford individualized, precision therapeutic strategies for patients with early-stage rNSCLC, thereby augmenting the efficacy of neoadjuvant and adjuvant therapies. This article delves into an in-depth elucidation of these consensus recommendations.